At least six major hospitals reached agreements with the Trump administration by 22 September 2026 to cease offering gender-affirming hormones and surgery to transgender young people and to make alternative payments. The deals represent a coordinated shift in hospital policy aligned with the administration's stance on transgender youth medical care.
Health policy experts questioned the efficacy of President Trump's administration's 'most-favored-nation' drug pricing program announced on September 19, with concerns over whether patients will actually benefit. The program aims to involve all 50 states.
The Trump administration announced new Medicaid drug pricing agreements with nine mid-sized biotechnology and pharmaceutical companies on August 31, including UCB SA, Bridgebio Pharma, and Sun Pharmaceutical. The administration stated all negotiated drugs will be priced at the lowest available rates.
On August 11, 2026, the Trump administration finalized a rule prohibiting federal Medicaid and CHIP funding for hormone therapy, puberty blockers, and surgeries for transgender youth under 19. Hospitals halted such services, leaving intersex and transgender minors without critical treatment.